American Superconductor Corporation (BIT:1AMSC)

Verve Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	207.89	79.49	90.52	23.36	40.58	67.81
Short-Term Investments	-	-	-	-	-	5.14
Cash & Short-Term Investments	207.89	79.49	90.52	23.36	40.58	72.95
Cash Growth	122.45%	-12.18%	287.51%	-42.44%	-44.37%	33.01%
Accounts Receivable	54.68	46.19	26.33	30.67	20.28	13.27
Receivables	54.68	46.19	26.33	30.67	20.28	13.27
Inventory	71.6	71.17	41.86	36.99	23.67	13.31
Prepaid Expenses	13.33	8.06	7.3	13.43	7.05	3.55
Restricted Cash	1.35	1.61	0.47	1.73	2.75	2.16
Total Current Assets	348.86	206.52	166.47	106.17	94.34	105.23
Property, Plant & Equipment	42.56	42.4	13.42	15.17	17.16	12.74
Long-Term Investments	1.41	1.11	-	-	-	-
Goodwill	48.16	48.16	43.47	43.47	43.47	34.63
Other Intangible Assets	5.58	5.92	6.37	8.53	11.31	9.15
Long-Term Deferred Tax Assets	1.26	1.18	1.12	1.11	1.22	1.22
Other Long-Term Assets	5.02	5.23	1.93	1.11	6.39	5.88
Total Assets	452.85	310.52	232.77	175.56	173.89	168.87
Accounts Payable	11.86	6.73	4.48	13.94	13.19	5.35
Accrued Expenses	18.12	20.85	14.68	11.57	9.68	10.85
Current Portion of Long-Term Debt	-	-	0.03	0.08	0.07	-
Current Portion of Leases	0.85	0.69	0.72	0.81	0.75	0.61
Current Income Taxes Payable	0.45	0.31	0.35	0.41	0.41	0.52
Current Unearned Revenue	66.06	66.8	50.73	43.57	22.81	13.27
Other Current Liabilities	7.97	4.4	7.83	13.74	7.07	10.14
Total Current Liabilities	105.31	99.76	78.81	84.11	53.96	40.74
Long-Term Debt	-	-	-	0.02	0.09	-
Long-Term Leases	2.91	2.68	1.97	2.18	2.9	3.25
Long-Term Unearned Revenue	9.84	9.34	7.1	7.19	7.22	7.99
Long-Term Deferred Tax Liabilities	1.65	1.6	0.3	0.24	0.3	0.27
Other Long-Term Liabilities	0.03	0.03	0.03	0.03	0.03	0.03
Total Liabilities	119.73	113.41	88.2	93.76	64.5	52.27
Common Stock	0.46	0.4	0.37	0.3	0.29	0.28
Additional Paid-In Capital	1,389	1,260	1,213	1,139	1,134	1,121
Retained Earnings	-1,054	-1,061	-1,067	-1,056	-1,021	-1,001
Treasury Stock	-3.77	-3.77	-3.64	-3.64	-3.64	-3.59
Comprehensive Income & Other	1.38	1.57	1.58	1.57	-0.29	-0.28
Shareholders' Equity	333.12	197.11	144.57	81.8	109.39	116.59
Total Liabilities & Equity	452.85	310.52	232.77	175.56	173.89	168.87
Total Debt	3.76	3.37	2.71	3.08	3.8	3.86
Net Cash (Debt)	204.13	76.13	87.81	20.28	36.78	69.1
Net Cash Growth	128.78%	-13.31%	333.05%	-44.87%	-46.77%	22.39%
Net Cash Per Share	5.27	2.02	2.94	0.73	1.35	2.89
Filing Date Shares Outstanding	45.16	39.5	36.99	29.6	28.52	28.02
Total Common Shares Outstanding	45.16	39.48	36.95	29.54	28.52	27.59
Working Capital	243.55	106.75	87.66	22.07	40.37	64.49
Book Value Per Share	7.38	4.99	3.91	2.77	3.84	4.23
Tangible Book Value	279.37	143.03	94.73	29.8	54.61	72.81
Tangible Book Value Per Share	6.19	3.62	2.56	1.01	1.91	2.64
Land	22.65	22.65	0.98	0.98	0.98	0.27
Buildings	7.53	7.53	5.42	5.42	5.27	1.63
Machinery	50.06	49.45	45.62	44.69	45.05	42.99
Construction In Progress	1.54	1.37	0.23	0.75	0.57	0.22
Leasehold Improvements	8.03	7.97	6.99	6.82	6.63	6.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.